AbCellera Biologics Quarterly Cash Flow Statement
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics free cash flow
In the quarter ended Jun 30, 2026, AbCellera Biologics generated $25.9 million of operating cash flow and spent $2.1 million on capital expenditures. That left free cash flow of $23.8 million, a free-cash-flow margin of 587.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -55.43M | -43.16M | -8.95M | -57.12M | -34.73M | -45.62M | -34.21M | -51.11M | -36.93M | -40.61M | -47.15M | -28.61M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -207.46% |
| Depreciation & Amortization | 6.99M | 6.84M | 5.18M | 5.25M | 5.47M | 5.33M | 2.10M | 36.92M | 36.52M | 4.84M | 7.54M | 5.74M |
| Stock-Based Compensation | 12.29M | 12.01M | 12.90M | 13.89M | 14.21M | 14.79M | 15.23M | 17.16M | 17.78M | 17.41M | 16.45M | 15.86M |
| Change in Working Capital | 48.53M | -6.08M | -35.36M | -4.78M | -13.16M | 16.09M | -3.75M | -13.89M | -13.74M | -35.08M | -3.24M | -4.44M |
| Operating Cash Flow | 25.92M | -33.52M | -34.74M | -52.59M | -32.40M | -11.55M | -8.00M | -28.88M | -29.97M | -41.71M | -19.61M | -106.00K |
| Capital Expenditures | -2.13M | -3.83M | -9.84M | -8.93M | -13.37M | -10.64M | -15.63M | -18.52M | -20.11M | -24.14M | -14.43M | -20.33M |
| Investing Cash Flow | 11.34M | -25.08M | 75.14M | 36.49M | -31.81M | 7.93M | 35.70M | 3.70M | 52.10M | 29.91M | -24.32M | -12.79M |
| Debt Issued | — | — | — | — | — | — | — | 3.10M | 2.37M | 2.12M | — | 6.56M |
| Financing Cash Flow | 6.39M | 7.19M | 4.12M | 7.37M | -3.38M | 5.97M | 4.14M | 3.15M | 2.65M | 2.83M | 3.77M | 6.63M |
| Net Change in Cash | 43.23M | -51.45M | 44.80M | -9.28M | -66.83M | 2.94M | 29.68M | -21.67M | 24.74M | -9.75M | -39.10M | -7.33M |
| Free Cash Flow | 23.79M | -37.35M | -44.59M | -61.52M | -45.77M | -22.19M | -23.63M | -47.40M | -50.08M | -65.85M | -34.04M | -20.44M |
This table shows 12 quarterly periods of AbCellera Biologics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a cash flow statement?